# Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation

> **NCT00989469** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 64 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Nexavar (Sorafenib) and irinotecan (Campto)

## Key facts

- **NCT ID:** NCT00989469
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-02
- **Final completion:** 2012-02
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989469, "Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00989469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*